Who Might Benefit from Long-Term DAPT? Risk Score May Help (FREE)

By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Researchers have developed a risk score to determine which percutaneous coronary intervention (PCI) patients would benefit most from continuing dual antiplatelet therapy (DAPT) beyond 12 months, according to results presented at the American Heart Association's annual meeting.In the DAPT study, nearly 12,000 patients who'd …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news